Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | -17.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.33 | N/A | -17.86% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a commitment to their clinical pipeline but did not offer any forward-looking guidance. The tone was cautious regarding future expectations.
Management did not provide specific guidance for future performance.
The company is focused on advancing its clinical programs.
The earnings report indicates that Day One Biopharma is still in the early stages of its development, as reflected by the lack of revenue and a loss per share. The stock fell 5.7% following the announcement, likely due to the missed EPS and the absence of guidance, which may leave investors uncertain about the company's near-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UBIQUITI INC
Nov 5, 2021